Boomi Recognized as a Leader in the 2025 Gartner ® Magic Quadrant™ for API Management
Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management. This recognition reflects Boomi’s strength in both ability to execute and completeness of vision, which in Boomi’s view, reaffirms the company’s focus on powering API innovation at the core of agentic transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013735773/en/
Boomi Recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management
“As organizations race to unlock the full value of agentic AI, APIs have never been more critical,” said Steve Lucas, Chairman and CEO at Boomi. “That’s why it’s so meaningful that Boomi is the only vendor recognized as a Leader in both the 2025 Gartner® Magic Quadrant™ for API Management and the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service. Boomi enables enterprises to manage, unify, and orchestrate APIs alongside AI agents, data, and applications, all within ONE platform. Our vision remains clear: connect everything to achieve anything.”
A Leader in Vision and Execution
Boomi is redefining API management for enterprises as a foundational capability of its broader AI-driven platform strategy. In last year's report, Boomi was positioned as a Niche Player. Boomi believes the improvement in its position highlights that its strengths lie not only in innovation but also in how the company delivers results at scale.
With a well-rounded, cloud-native platform, Boomi helps organizations tame API sprawl, scale securely, and deliver trusted data for AI. Recent enhancements build on the company’s product strategy, combining federated API management, runtime flexibility, security, and agentic AI support to accelerate innovation while maintaining enterprise-grade reliability.
Boomi’s integrated approach ensures centralized API governance across multi-gateway environments without introducing runtime latency, unlocking a new level of agility, composability, and compliance.
Global Reach and Ecosystem Expansion
Boomi’s APIM capabilities are strengthened through its global partner network and strategic alliances, particularly with ServiceNow and Amazon Web Services (AWS). These partnerships enable customers to streamline digital workflows and securely orchestrate agentic AI, accelerating their business transformation and ability to scale.
One Platform for Agentic Transformation
According to Boomi, the company's position in this year’s Gartner Magic Quadrant for API Management reflects a broader market shift toward converged integration, API, data, and AI agent orchestration. As part of the Boomi Enterprise Platform, Boomi API Management integrates seamlessly with Boomi Agentstudio, Boomi DataHub, and Boomi Data Integration, providing enterprises with a single control plane to fuel innovation and translate it into measurable business impact.
Additional Resources
- See why Boomi was recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management here
- View the 2025 Gartner® Magic Quadrant™ for API Management here
- Follow Boomi on X, LinkedIn, Facebook, and YouTube
Gartner Disclaimer:
Gartner® Magic Quadrant™ for API Management, Shameen Pillai, Steve Shwent, John Santoro, Nicholas Carter, October 7, 2025.
Gartner is a registered trademark and service mark, and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Boomi
Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘Boomi’ logo, the ‘B’ logo, and Boomiverse are registered trademarks of Boomi, LP or its subsidiaries or affiliates in the US and other countries. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013735773/en/
Contacts
Analyst Relations Contact:
Kate Mauser
Analyst Relations
kate.mauser@boomi.com
+1.760.351.6780
Media Relations Contact:
Brandon Gubitosa
Global Corporate Communications
brandon.gubitosa@gmail.com
+1.845.642.5798
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom